Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3059-3061

  Sauer, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast cancer; CA 15 3; CEA; Follow up; MCA; Therapeutic intervention; Tumor markers

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; TUMOR MARKER;

BREAST CANCER; CANCER RECURRENCE; CONFERENCE PAPER; FEMALE; FOLLOW UP; GERMANY; HUMAN; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY;

BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030767544     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Basuyau JP, Brunelle P, Charrot P, Chevallier B, Delapierre F, Graic Y, Julien JP, Veyret C: Ca 15.3 et diagnostic précoce de récidive dans les cancers du sein. Bull Cancer 80: 213-218, 1993.
2. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30: 117-126, 1994.
3. Del Turco MR, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V (for the National Research Council Project on Breast Cancer Follow-up): Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. J Am Med Assn 271: 1593-1597, 1994.
4. Donegan WL: Follow-up after treatment for breast cancer: How much is too much? J Surg Oncol 59: 211-214, 1995.
5. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD: Meeting highlights - International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 14411445, 1995.
6. Graeff H: Tumorbiologie-orientierte Behandlungskonzepte in der gynäkologischen Onkologie. Geburtsh u Frauenheilk 55: M27-M31, 1995.
7. Hellriegel KP, Schulz HD: Nachsorge bei Mammakarzinom-Patientinnen. Empfehlungen einer Konsensus-Tagung, Berlin 23.-24-02. 1995. Onkologe 1: 405-412, 1995 .
8. Hellriegel KP, Schulz HD: Nachsorge bei Mammakarzinom-Patientinnen. Empfehlungen einer Konsensus-Tagung. Forum 10: 272-274, 1995.
9. Hilsenbeck SG, Clark GM, McGuire WL: Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 22: 197-206, 1992.
10. Jäger W: The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements. Eur J Cancer Prevention 2: 133-139, 1993 Suppl 3.
11. Jäger W, Krämer S, Palapelas V, Norbert L: Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest 55: 87-92, 1995 Suppl 221.
12. Jäger W: Disseminated breast cancer: does early treatment prolong survival without symptoms? The Breast 4: 65 (Abstract No 4) 1995.
13. Kattlove HA, Liberati A, Keeler E, Brook RH: Benefits and costs of screening and treatment for early breast cancer. J Amer Med Assn 273: 142-148, 1995.
14. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S: Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized study. Cancer Chemother Pharmacol 35: 80-83, 1994.
15. Levine MN, Browman GP, Gent M, Roberts R, Goodyear M: When is a prognostic factor useful?: a guide for the perplexed. J Clin Oncol 9: 348-356, 1991.
16. Mansour EG: The value of prognostic factors in selecting node-negative breast cancer patients for adjuvant therapy. J Surg Oncol 49: 73-75, 1992.
17. McGuire WL, Clark GM: Current concepts: prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med. 326: 1756-1761, 1992.
18. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Giménez N, Pahisa J, Velasco M, Ballestra AM: Breast Cancer Res Treat 36: 41-48, 1995.
19. Noguchi M, Miyazaki I: Prognostic factors in breast cancer and their controversies (review). Oncology Reports 1: 1157-1163, 1994.
20. Ravdin PM: A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy. Breast Cancer 8: 197-211, 1994.
21. Sauer H: Significance of prognostic factors for treatment selection in breast cancer patients. Electronic Journal of Pathology and Histology (in press) 1996.
22. Sauer H, Hölzel D: Mammakarzinom-Nachsorge: Ist eine routinemäßige apparative Nachsorge bei symptomfreien Frauen sinnvoll? - Fragen zur Effektivität von Skelettszintigraphie, Röntgenaufnahmen des Thorax, Lebersonographie, Mammographie und Laboruntersuchungen einschließlich Tumormarkern. Fortschritte der Medizin 113: 183-187 (Teil 1), 210-214 (Teil 2) 1995.
23. The GIVIO Investigators: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. J Am Med Assn 271: 1587-1592, 1994.
24. Wood WC: Integration of risk factors to allow patient selection for adjuvant systemic therapy in lymph node-negative breast cancer patients. World J Surg 18: 39-44, 1994.